![[HTML version]](/e/graphics/htmlborder.gif)
![[PDF version]](/e/graphics/pdfborder.gif)
![[CIF]](/e/graphics/cifborder.gif)
![[3d view]](/e/graphics/3dviewborder.gif)
![[Structure Factors]](/e/graphics/structurefactorsborder.gif)
![[Supplementary Material]](/e/graphics/supplementarymaterialsborder.gif)
![[CIF check Report]](/e/graphics/checkcifborder.gif)
![[Open access]](/e/graphics/free.gif)
![[Contents scheme]](at2812contents.gif)
Acta Cryst. (2009). E65, m806 [ doi:10.1107/S1600536809022831 ]
Abstract: In the crystal structure of the title compound {systematic name: diaquabis[1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylato]manganese(II) 2,2'-bipyridine solvate tetrahydrate}, [Mn(C16H17FN3O3)2(H2O)2]·C10H8N2·4H2O, the pyridone O atom and one carboxylate O atom of the two norfloxacin ligands are bound to the MnII ion, which is located on an inversion centre, and occupy equatorial positions, while two aqua O atoms lie in apical positions, resulting in a distorted octahedral geometry. The crystal packing is stabilized by N-H
O and O-H
O hydrogen-bonding interactions.
Online 20 June 2009
Copyright © International Union of Crystallography
IUCr Webmaster